COR1167
A Phase 1, Dose-Escalating, Randomized, Placebo-Controlled, 3-Part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of COR-1167 in Healthy Subjects and Subjects with Chronic Heart Failure
- Stage
- inclusie
- Medicine
- COR-1167
- Population
- Hartfalen
- Phase
- I
- First Patient In
- 7 May 2024
- Last Patient In
- 1 December 2025
- Last Patient Last Visit
- 25 December 2025
Inclusion period, 2 days remaining
National Lead
prof. dr. A. Voors
Cardioloog
Board Contact
dr. S. van Wijk
Cardioloog
Office Contact
